Active substanceCalcium chlorideCalcium chloride
Similar drugsTo uncover
  • Calcium chloride
    solution in / in 
  • Calcium chloride
    solution in / in 
  • Calcium chloride
    solution in / in 
    BIOCHEMIST, OJSC     Russia
  • Calcium chloride
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Calcium chloride
    solution in / in 
  • Calcium chloride
    solution in / in 
    SYNTHESIS, OJSC     Russia
  • Calcium chloride
    solution in / in 
  • Calcium chloride
    solution in / in 
  • Calcium chloride
    concentrate d / infusion 
  • Calcium chloride
    solution in / in 
    Mapichem AG     Switzerland
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    Composition per ml:

    Active substance: calcium chloride hexahydrate - 100 mg.

    Excipients: water for injection up to 1 ml.

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:Calcium-phosphorus exchange regulator
    ATX: & nbsp

    B.05.X.A   Electrolyte solutions

    B.05.X.A.07   Calcium chloride

    Pharmacodynamics:

    The preparation of calcium replenishes the deficiency of calcium ions necessary for the process of nerve impulse transmission, reduction of skeletal and smooth muscles, myocardial activity, formation of bone tissue, the process of blood coagulation, and the functioning of other systems and organs.

    Calcium is the co-factor of many enzymes and therefore affects the secretory activity of the endocrine and exocrine glands.

    The decrease in the content of calcium ions in the blood plasma and tissues can lead to the development of various pathological processes. Hypocalcemia leads to the development of tetany and spasmophilia, the violation of the functions of skeletal and smooth muscles, the cardiovascular system, the disruption of the blood coagulation system, the development of osteoporosis.

    Calcium chloride, in addition to eliminating hypocalcemia, reduces vascular permeability and has an anti-allergic effect.

    With intravenous injection stimulates the sympathetic division of the autonomic nervous system, enhances the secretion of epinephrine by the adrenal glands, and has a moderate diuretic effect.

    Pharmacokinetics:In the blood, calcium is in the ionized and bound state. In plasma about 45% of calcium is in a complex with proteins. Ionized calcium has physiological activity. It is deposited in bone tissue. About 20% of the drug is excreted by the kidneys, the rest (80%) is the intestine. 95% of calcium emitted by glomerular filtration,is subjected to absorption in the ascending segment of the Henle loop, as well as in the proximal and distal renal tubules.
    Indications:

    - allergic diseases (hives, angioedema, allergic dermatoses, serum sickness);

    - hypocalcemia (including hypocalcemia tetany, with hypoparathyroidism);

    - lead colic;

    - hyperkalemia;

    - overdose of magnesium salts (as part of complex therapy).

    Contraindications:

    Hypersensitivity to the drug, hypercalcemia, severe chronic renal failure, ventricular fibrillation, urolithiasis, sarcoidosis, arteriosclerosis expressed, susceptibility to thrombosis, simultaneous with cardiac glycosides, pregnancy, lactation.

    Carefully:

    Chronic renal failure mild to moderate severity, dehydration, electrolyte imbalance (the risk of hypercalcemia), heart disease (risk of arrhythmia), renal disease, "pulmonary" heart, respiratory acidosis, respiratory failure (risk of toxic reactions due to the oxidation of calcium).

    Pregnancy and lactation:

    During pregnancy and during breastfeeding, the drug is contraindicated.

    If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.

    Dosing and Administration:

    The drug is injected intravenously in droplets or drip (slowly) at a rate of no more than 0.75 - 1.5 ml / min. The ampoule with the solution before the introduction is heated to the temperature of the body. After completion of the administration, the patient should remain for a short time in the "lying" position.

    For intravenous drip, the drug solution is first diluted in 100-200 ml of 0.9% isotonic sodium chloride solution or 5% dextrose (glucose) solution.

    With allergic reactions (urticaria, angioedema, allergic dermatosis, serum sickness), lead colic, overdose of magnesium salts - 7.5-15 ml.

    In acute hypocalcemia - 7,5-15 ml for 1-3 days, if necessary, the administration is repeated every 1-3 days.

    With hypocalcemic tetany - 5-17.5 ml. The administration is repeated every 8 hours until a therapeutic effect is achieved.

    With giperkaliemii (under the control of the electrocardiogram) - 2.45-15 ml, if necessary, the repeated dose is administered after 1-2 minutes.

    Children - 0.3 ml / kg, the maximum daily dose - 15 ml.

    In allergic diseases, the combined use of calcium chloride and antihistamines is recommended.

    Side effects:

    With intravenous administration, it is possible to feel the heat first in the oral cavity, and then throughout the body, the taste of chalk in the mouth, peripheral vasodilation, lowering blood pressure, arrhythmia (including bradycardia), nausea, fainting.

    When ingested in the subcutaneous fat and muscle, it causes severe irritation and necrosis of surrounding tissues.

    With rapid administration, ventricular fibrillation, cardiovascular failure, up to cardiac arrest are possible.

    Local reactions: irritation along the veins; hyperemia of the skin, pain, rash,

    calcification may indicate extravasation, which can lead to necrosis of surrounding tissues.

    Overdose:

    Symptoms: hypercalcemia (thirst, nausea, vomiting, constipation, polyuria, abdominal pain, muscle weakness, mental disorders, in severe cases - arrhythmia, coma), especially in patients with chronic renal failure.

    Treatment: with mild overdose (calcium concentration - 2,6-2,9 mmol / l), the administration is stopped and other calcium-containing drugs are canceled.In severe overdose (calcium concentration more than 2.9 mmol / l) - the introduction of 0.9% isotonic sodium chloride solution; non-diasidic diuretics; monitoring of serum concentration, if necessary, administration of potassium and magnesium preparations; control cardiac activity, the introduction of beta-adrenoblockers for the prevention of arrhythmias, hemodialysis.

    Interaction:

    With simultaneous application reduces the effect of blockers of "slow" calcium channels; with other calcium and magnesium preparations, the risk of hypercalcemia or hypermagnesia, respectively, increases, especially in patients with chronic renal insufficiency; with quinid - possibly slowing the intraventricular conduction and increasing the toxicity of quinidine.

    Reduces the effectiveness of nondepolarizing muscle relaxants. May increase the duration of action of tubocurarine chloride.

    Pharmaceutically incompatible with tetracyclines, magnesium sulfate, drugs containing phosphates, carbonates or tartrates.

    During the treatment with cardiac glycosides parenteral application of calcium chloride is not recommended in connection with the intensification of cardiotoxic action.

    Special instructions:

    Do not administer subcutaneously and intramuscularly!

    When calcium chloride enters the skin or in muscle tissue, a strong local tissue irritation develops with the formation of foci of necrosis.

    Treatment is carried out under the control of the concentration of calcium in the blood.

    Effect on the ability to drive transp. cf. and fur:During the treatment period, due to the possible development of side effects, care must be taken when driving vehicles and engaging in potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.
    Form release / dosage:Solution for intravenous administration is 100 mg / ml.
    Packaging:

    A solution for intravenous administration of 100 mg / ml in ampoules of 5 or 10 ml.

    For 10 ampoules together with instructions for use in a pack of cardboard.

    5 ampoules are placed in a contour mesh package. 2 contour mesh packages along with the instruction for use are placed in a pack of cardboard.

    In each pack insert knife ampoule or scarifier.

    When packing ampoules with a break point or a fracture ring, the ampoule knife or scarifier is not inserted.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-007953/08
    Date of registration:08.10.2008
    The owner of the registration certificate:Armavir Biofactory, FKPArmavir Biofactory, FKP Russia
    Manufacturer: & nbsp
    Information update date: & nbsp14.09.2015
    Illustrated instructions
      Instructions
      Up